Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Pharmaceutical composition for treating chronic heart failure

A technology for chronic heart failure and composition, applied in the field of medicine, can solve the problems of cerebral thrombosis, stasis, and the overall effective rate of heart failure treatment is not ideal.

Inactive Publication Date: 2017-01-11
SHENZHEN AUSA PHARM CO LTD +1
View PDF2 Cites 1 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0009] At present, the overall effective rate of clinical heart failure treatment is not ideal, and long-term heart failure makes the blood flow of the body's circulatory system slow and stagnant, which can easily lead to cerebral thrombosis

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Pharmaceutical composition for treating chronic heart failure
  • Pharmaceutical composition for treating chronic heart failure
  • Pharmaceutical composition for treating chronic heart failure

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0031] Example 1. Preparation of Sacubitra 20mg / Enalapril 5mg / Folic Acid 0.4mg Tablets (1000 Tablets)

[0032]

[0033] Preparation method: pass the auxiliary materials through a 80-mesh sieve, and dry for later use. Take 25g of anhydrous dibasic calcium phosphate and 5g of enalapril maleate and mix them uniformly according to the method of equal increase, and add sacubitril, folic acid, microcrystalline cellulose, carboxymethyl starch sodium, and crospovidone respectively according to the prescription amount. Ketone and anhydrous calcium hydrogen phosphate, made of soft material with 2% hydroxypropyl methylcellulose solution, granulated with a 20-mesh sieve, dried at 40°C for about 2 hours, granulated with a 20-mesh sieve, and the water content of the granules is controlled to be 2- 3%, the dried granules are mixed evenly with magnesium stearate and talcum powder, the semi-finished product is tested, and the content is measured, and it is compressed into 1000 tablets with ...

Embodiment 2

[0034] Example 2. Preparation of Sacubitril 30mg / Ramipril 2.5mg / Folic Acid 0.4mg Tablets (1000 Tablets)

[0035]

[0036] Preparation method: the auxiliary material is a direct pressing auxiliary material, which is dried for later use. Take 30 g of ramipril, folic acid and microcrystalline cellulose in the prescribed amount and mix them uniformly according to the method of equal increase to obtain mixed powder 1; weigh the remaining prescribed amount of microcrystalline cellulose, lactose, and croscarmellose sodium , colloidal silicon dioxide, fully mixed with Shakubi koji to obtain mixed powder 2; mixed powder 1 and mixed powder 2 with the prescribed amount of glyceryl behenate, to obtain the final mixed powder intermediate, and to detect the mixed powder Powder intermediate, pressed into 1000 tablets. Pay attention to avoiding light during the preparation process, and the prepared tablets need to be packed in aluminum-plastic blisters and stored away from light.

Embodiment 3

[0037] Example 3. Preparation of Sacubitra 40mg / Benazepril 10mg / Folic Acid 0.4mg Capsules (1000 Capsules)

[0038]

[0039] Preparation method: sieve the raw and auxiliary materials with 80 meshes, and dry them for later use. Take 40g of sacubit, 10g of benazepril, and 0.4g of folic acid and mix them uniformly according to the method of equal increase, then add lactose, microcrystalline cellulose, sodium carboxymethyl starch and low-substituted hydroxypropyl cellulose, mix well, and use 2% hypromellose solution to make soft material, granulate with 20-mesh sieve, dry at 40°C for about 2 hours, granulate with 20-mesh sieve, control the water content of the granules to 2-3%, mix the dried granules with talcum powder Mix evenly, test the semi-finished product, measure the content, and put it into a hollow capsule.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
Diameteraaaaaaaaaa
Login to View More

Abstract

The invention relates to a pharmaceutical composition comprising an angiotensin converting enzyme inhibitor (ACEI), an enkephalinase inhibitor, a folic acid compound and a pharmaceutically acceptable carrier, wherein the ACEI is selected from the group consisting of enalapril, benazepril, ramipril, fosinopril, cilazapril, perindopril and the like, and the content is 1.25-75 mg; the enkephalinase inhibitor is sacubitril, and the content is 10-120 mg; and the folic acid compound is selected from the group consisting of folic acid, 5-methyltetrahydrofolate, calcium formyltetrahydrofolate, leucovorin, calcium levofolinate and the like, and the content is 0.1-5 mg. The invention provides the use of the pharmaceutical composition in the preparation of a medicament for the treatment of chronic heart failure and the prevention of stroke. By the implementation of the invention, the pharmaceutical composition can also improve the compliance of patients and improve the therapeutic effect by providing the pharmaceutical composition for a specific use to the patients.

Description

technical field [0001] The invention relates to a pharmaceutical composition of an angiotensin-converting enzyme inhibitor (ACEI), a neprilysin inhibitor and a folic acid compound and an application thereof, belonging to the field of medicine. Background technique [0002] Hypertension is one of the most common chronic diseases and the most important risk factor for cardiovascular and cerebrovascular diseases. Its main complications such as stroke, myocardial infarction, heart failure and chronic kidney disease have a high disability and fatality rate, which seriously consumes medical treatment. resources, which impose a heavy burden on families and society. The main goal of hypertension treatment is to minimize the overall risk of cardiovascular complications and death, and it is necessary to treat all reversible cardiovascular risk factors, subclinical target organ damage, and various coexisting clinical diseases [Chinese Hypertension Prevention and Treatment]. Guidelines...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): A61K45/06A61K38/05A61P9/04A61K31/216A61K31/40A61K31/519A61K31/55
CPCA61K45/06A61K9/2054A61K9/2059A61K9/4866A61K31/216A61K31/40A61K31/519A61K31/55A61K38/05A61K2300/00
Inventor 张磊徐希平刘平
Owner SHENZHEN AUSA PHARM CO LTD
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com